Medicenna Therapeutics Corp. (MDNA.TO) Deep Dive Video

Name: Medicenna Therapeutics Corp. (MDNA.TO) Deep Dive Video | Flash
Uploaded: 2025-12-20T16:04:40.385
Description: A clinically validated, beta-only IL-2 “Superkine” trading at a microcap valuation—Medicenna’s upside hinges on solving the mid-2026 funding cliff via partnership or acquisition.

Summary

A clinically validated, beta-only IL-2 “Superkine” trading at a microcap valuation—Medicenna’s upside hinges on solving the mid-2026 funding cliff via partnership or acquisition.

View MDNA.TO stock page · Read the MDNA.TO research report

Loading the video player…